[go: up one dir, main page]

WO2011140446A3 - Formulations pharmaceutiques - Google Patents

Formulations pharmaceutiques Download PDF

Info

Publication number
WO2011140446A3
WO2011140446A3 PCT/US2011/035529 US2011035529W WO2011140446A3 WO 2011140446 A3 WO2011140446 A3 WO 2011140446A3 US 2011035529 W US2011035529 W US 2011035529W WO 2011140446 A3 WO2011140446 A3 WO 2011140446A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulations
drug
effective
amount
particleses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/035529
Other languages
English (en)
Other versions
WO2011140446A2 (fr
Inventor
Irukulla Srinivas
Chakole Dinesh Dayaramji
Pradeep Kumar Reddy Chellekkagari
Gali Amar Babu
Mundada Veenu Piyush
Satuluri Satya Sivaram
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Inc
Original Assignee
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd, Dr Reddys Laboratories Inc filed Critical Dr Reddys Laboratories Ltd
Publication of WO2011140446A2 publication Critical patent/WO2011140446A2/fr
Publication of WO2011140446A3 publication Critical patent/WO2011140446A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique formée de particules, pour une utilisation orale. Ladite composition comprend a) des noyaux comprenant une quantité efficace d'un médicament à base de benzimidazole substitué et un agent stabilisant, présent en une quantité efficace pour stabiliser le médicament, b) une couche intermédiaire/barrière et c) une couche de revêtement entérique externe. Les particules revêtues peuvent en outre être enrobées et cogranulées avec un ou plusieurs excipients.
PCT/US2011/035529 2010-05-06 2011-05-06 Formulations pharmaceutiques Ceased WO2011140446A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1270CH2010 2010-05-06
IN1270/CHE/2010 2010-05-06
US36202810P 2010-07-07 2010-07-07
US61/362,028 2010-07-07

Publications (2)

Publication Number Publication Date
WO2011140446A2 WO2011140446A2 (fr) 2011-11-10
WO2011140446A3 true WO2011140446A3 (fr) 2012-03-15

Family

ID=44904501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/035529 Ceased WO2011140446A2 (fr) 2010-05-06 2011-05-06 Formulations pharmaceutiques

Country Status (1)

Country Link
WO (1) WO2011140446A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2345408A3 (fr) * 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Formulations de médicament labiles acides
AU2014246617A1 (en) * 2013-12-23 2015-07-09 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
CA2910865C (fr) 2014-07-15 2016-11-29 Isa Odidi Compositions et methodes destines a reduire les surdoses
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN105001199A (zh) * 2015-05-13 2015-10-28 济南大学 N-甲基埃索美拉唑的制备方法
US11045550B2 (en) 2016-05-13 2021-06-29 Merck Patent Gmbh Use of an amino sugar as plasticizer
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP2021046372A (ja) * 2019-09-19 2021-03-25 日医工株式会社 エソメプラゾール含有製剤
EP4072532B1 (fr) 2019-12-11 2024-01-24 Evonik Operations GmbH Forme galénique destinée à être utilisée dans le traitement ou la prévention d'une maladie
WO2021115649A1 (fr) * 2019-12-11 2021-06-17 Evonik Operations Gmbh Forme posologique à utiliser dans le traitement ou la prévention d'une maladie
WO2024120944A1 (fr) * 2022-12-09 2024-06-13 Evonik Operations Gmbh Composition à libération retardée résistante aux conditions gastriques à l'état nourri

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042277A1 (en) * 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
US20050214372A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20060051421A1 (en) * 2004-06-15 2006-03-09 Nava Shterman Stable pharmaceutical formulations of benzimidazole compounds
US20090208575A1 (en) * 2005-01-03 2009-08-20 Lupin Limited Pharmaceutical Composition Of Acid Labile Substances
WO2010041276A1 (fr) * 2008-10-06 2010-04-15 Jubilant Organosys Limited Compositions pharmaceutiques comprenant de l’ésoméprazole amorphe, formes pharmaceutiques et procédé associés

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042277A1 (en) * 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
US20050214372A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
US20060051421A1 (en) * 2004-06-15 2006-03-09 Nava Shterman Stable pharmaceutical formulations of benzimidazole compounds
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20090208575A1 (en) * 2005-01-03 2009-08-20 Lupin Limited Pharmaceutical Composition Of Acid Labile Substances
WO2010041276A1 (fr) * 2008-10-06 2010-04-15 Jubilant Organosys Limited Compositions pharmaceutiques comprenant de l’ésoméprazole amorphe, formes pharmaceutiques et procédé associés

Also Published As

Publication number Publication date
WO2011140446A2 (fr) 2011-11-10

Similar Documents

Publication Publication Date Title
WO2011140446A3 (fr) Formulations pharmaceutiques
WO2012085657A3 (fr) Formes pharmaceutiques solides à usage oral résistant à la contrefaçon
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
WO2008146178A3 (fr) Nouvelle forme posologique de comprimé
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
IL233677A (en) Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
PH12014501446B1 (en) Solid nicotine-comprising dosage form with reduced organoleptic disturbance
PL2808325T3 (pl) Podstawione azole, przeciwwirusowy składnik czynny, kompozycja farmaceutyczna, sposób ich wytwarzania i stosowania
MX2013001985A (es) Formulaciones a base de nalbufina y sus usos
CR20150077A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
WO2012001705A3 (fr) Compositions pharmaceutiques de (r)-lansoprazole
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
EP2150235A4 (fr) Formulation de capsules enrobées de nanoparticules pour administration dermique de médicament
BR112015027436A2 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
WO2012092486A3 (fr) Formulations de benzimidazole à libération modifiée
IL201959A (en) Annals 2 - (1-Acetyl-Piperidine-4-Il) -4,2- Dihydro-Pyrazole-3-On
PH12016500693A1 (en) Slow-release solid oral compositions
BR112012021445B8 (pt) formulação farmacêutica ou neutracêutica, e uso de um agente promotor de biodisponibilidade
IL223886B (en) A method to combat the clandestine administration of chemicals, the use of a dye to combat the clandestine administration of chemicals and a pharmaceutical preparation that enables the application of the method
WO2012156997A3 (fr) Composition pharmaceutique contenant plusieurs particules
IL210975A (en) Annapomapungin History, Pharmaceuticals Containing Them and Their Use in Preparing Medicines to Treat Fungal Infections
WO2012085249A3 (fr) Formes pharmaceutiques orales homogènes comprenant de la lercanidipine et de l'énalapril ou leurs sels pharmaceutiquement acceptables
WO2013017910A8 (fr) Compositions pharmaceutiques à libération prolongée contenant de la palipéridone
HUE041795T2 (hu) Bevonószer szilárd gyógyszerészeti készítményhez, gyógyszerészeti filmkészítmény, és bevonatos szilárd gyógyszerészeti készítmény
EP2345408A3 (fr) Formulations de médicament labiles acides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11778421

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11778421

Country of ref document: EP

Kind code of ref document: A2